Tempus AI stock has climbed 18.6% over the past week, yet the valuation checks send a mixed message, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader scorecard still leans expensive.

• The 18.6% gain in the past week signals renewed enthusiasm around Tempus AI, putting more pressure on the valuation to justify the move.
• Strong revenue momentum and new partnerships in data driven cancer research can support expectations for future cash flows, while insider share sales and the path to sustained profitability may keep some investors cautious.
• With a valuation score of 2 out of 6, Tempus AI does not screen as a clear bargain on the broader checks even though the DCF suggests it could be undervalued by about 36.8%.

The issue now is whether Tempus AI's current share price around US$61.60 still offers enough margin to align with that intrinsic value estimate.

Is Tempus AI Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model values Tempus AI by projecting its future cash generation and discounting it back to today. For Tempus AI, the latest twelve month free cash flow is a loss of $225.6 million. The model used here assumes recovering, growing cash flows over the next decade as the business scales.

Based on those projections, the DCF points to an estimated intrinsic value of about $97.51 per share, compared with the current share price around $61.60. This implies the stock screens roughly 36.8% below that cash flow based estimate. The recent research collaboration on rare cancer and growing attention on Tempus AI’s data and AI platform are among the reasons some investors may be willing to look past current losses and focus on the longer term cash flow potential.

On the cash flow math used here, Tempus AI stock currently appears undervalued relative to its DCF based intrinsic value estimate.

Our Discounted Cash Flow (DCF) analysis suggests Tempus AI is undervalued by 36.8%. Track this in your watchlist or portfolio, or discover 41 more high quality undervalued stocks.

Does Tempus AI Look Fairly Valued on Sales?

P/S is a useful cross check for Tempus AI because the company is still loss making, so earnings based multiples like P/E do not yet give a clear signal. On this metric, Tempus AI trades on a P/S of about 8.1x, which is above both the Life Sciences industry average of 4.1x and the peer group average of 4.7x.

The fair P/S ratio for Tempus AI, based on its growth profile, margins, size and risk, is estimated at 7.9x, only slightly below the current level. That narrow gap suggests the stock is not priced at a sharp premium or discount on sales, even after recent news around new research collaborations and management’s focus on improving profitability.

On the P/S yardstick, Tempus AI stock appears roughly fairly valued relative to what the model indicates could be a reasonable multiple for its fundamentals.

The Tempus AI Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Tempus AI build on this valuation puzzle by outlining which paths for Tempus AI's growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than its current price. These narratives are available on the company’s Community page. Each narrative links its number to a clear view of how Tempus AI's growth, profitability and risks could evolve, giving you something concrete to track as new information emerges.

Tempus AI inspires sharply different views in the community, with some focusing on the depth of its data platform and others on execution risk and future economics.

Bull case: 7% undervalued

"Every new test and partnership adds more data, making its AI models more valuable and creating opportunities to cross-sell additional products and services..."

Bear case: 6% overvalued

"Large technology and healthcare players are pushing into AI driven clinical data and diagnostics, and if they secure comparable datasets or tighter distribution with providers, Tempus AI's current advantage in proprietary data and hospital connectivity could erode over time..."

Do you think there's more to the story for Tempus AI? Head over to our Community to see what others are saying!

The Bottom Line

For Tempus AI, the Discounted Cash Flow (DCF) work points to meaningful upside relative to the current share price, while the P/S view suggests the stock is priced roughly in line with what the model treats as a reasonable sales multiple. That split, alongside a weaker overall value score, highlights how much the intrinsic value case depends on future cash flow improving from today’s losses. The core question from here is whether Tempus AI can convert its data and partnerships into a path to sustained, attractive profitability rather than the current discount reflecting execution and competitive risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.